Gilead CEO Daniel O'Day Sells $5.33 Million of Stock Under Trading Plan
Gilead Sciences Chairman and CEO Daniel O'Day sold 30,881 shares of the drugmaker's stock for $5.33 million over two trading days, according to a Form 4 filing Monday evening, with all of the trades made under a prearranged trading plan.
The filing said the transactions were made under a Rule 10b5-1 trading plan O'Day adopted on Feb. 25, 2026. Such plans let insiders schedule stock sales in advance.
Options exercised, then sold
On Oct. 30, O'Day exercised options to buy 15,881 Gilead shares at $72.34 each, then sold the same 15,881 shares at a weighted average price of $175.25, for proceeds of $2.78 million. Those options were set to expire on March 10, 2030.
On Nov. 2, he sold another 15,000 shares in five batches for $2.55 million, an average of $169.74 per share.
In total, the sales came to $5,329,178.
What he still holds
After the trades, O'Day directly owns 551,683 Gilead shares, according to the filing. He also holds 240,739 options from the same March 2030 grant that he did not exercise.
By the numbers
- Shares sold: 30,881
- Total sale value: $5.33 million
- Options exercised: 15,881 at $72.34
- Shares held directly after: 551,683
- 10b5-1 plan adopted: Feb. 25, 2026
Sources
- Form 4 filed by Gilead Sciences Chairman and CEO Daniel O'Day, filed Nov. 2, 2026 (accession 0001638643-26-000038)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.